The GATA-3–dependent transcriptome and tumor microenvironment are regulated by eIF4E and XPO1 in T-cell lymphomas

N Nermin Kady (University of Michigan, Ann Arbor, Michigan, United States) S Suhaib Abdelrahman (University of Michigan, Ann Arbor, Michigan, United States) A Ahmar M. Rauf (1Division of Hematology and Oncology, Department of Internal Medicine, University of Michigan, Ann Arbor, MI) A Alyssa Burgess J Jonathan Weiss (1Department I of Internal Medicine, Faculty of Medicine and University Hospital Cologne, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, German Chronic Lymphocytic Leukemia Study Group, University of Cologne, Cologne, Germany) H Hirushi Gunasekara N Neal Ramseier (1University of Illinois Chicago, Chemistry, Chicago, United States) I Ira P. Maine (1Division of Hematology and Oncology, Department of Internal Medicine, University of Michigan, Ann Arbor, MI) A Alejandro Zevallos-Morales V Vanessa Perez-Silos A Ashley Wolfe (1Division of Hematology and Oncology, Department of Internal Medicine, University of Michigan, Ann Arbor, MI) A Alexandra C. Hristov (5Department of Pathology, University of Michigan, Ann Arbor, MI) N Noah A. Brown (5Department of Pathology, University of Michigan, Ann Arbor, MI) K Kedar Inamdar (3Henry Ford Hospital, Depart of Pathology, Detroit, United States) M Maria Sverdlov Y Ying S. Hu (Department of Chemistry, University of Illinois Chicago, 845 W Taylor Street, Chicago, Illinois 60607, United States) C Carlos Murga-Zamalloa C Chenguang Wang R Ryan A. Wilcox (23Division of Hematology/Oncology, University of Michigan Cancer Center, Ann Arbor, MI)

Abstract

Abstract The transcription factor GATA-binding protein 3 (GATA-3) and the transcriptional program it regulates have emerged as oncogenic drivers across diverse T-cell lymphomas (TCLs), many of which are resistant to conventional chemotherapeutic agents and characterized by recurrent losses of key tumor suppressor genes, including TP53 and PTEN, both of which are clients of the nuclear export protein XPO1. Here, we demonstrated that XPO1 is highly expressed by malignant T cells expressing GATA-3 and by lymphoma-associated macrophages (LAMs) within their tumor microenvironment (TME). Using complementary genetically engineered mouse models, we demonstrated that TP53- and/or phosphate and tensin homolog (PTEN)-deficient TCLs, and LAMs within their TME, are sensitive to the selective exportin-1 (XPO1) antagonist selinexor. In an effort to identify TP53- and PTEN-independent mechanisms, we used complementary and orthogonal approaches to investigate the role of eIF4E and XPO1-dependent messenger RNA nuclear export in these TCLs. We identified a novel role for eIF4E/XPO1 in exporting GATA-3 and GATA-3–dependent transcripts from the nucleus in TCLs, and in the export of therapeutically relevant transcripts, including colony-stimulating factor-1 receptor, from LAMs. Therefore, XPO1 antagonism, by impairing oncogenic transcriptional programs in TCLs and depleting LAMs from their TME, is a novel approach to target 2 independent dependencies in a group of therapeutically challenging TCLs.

Article Details

Journal Blood
Volume / Issue Vol. 145, Issue 6
Published February 06, 2025
Pages 597-611
ISSN 0006-4971
Publisher Elsevier BV

Journal Info

Blood

Elsevier BV

ISSN: 0006-4971 Health Sciences

Authors (19)

N

Nermin Kady

University of Michigan, Ann Arbor, Michigan, United States

S

Suhaib Abdelrahman

University of Michigan, Ann Arbor, Michigan, United States

A

Ahmar M. Rauf

1Division of Hematology and Oncology, Department of Internal Medicine, University of Michigan, Ann Arbor, MI

A

Alyssa Burgess

J

Jonathan Weiss

1Department I of Internal Medicine, Faculty of Medicine and University Hospital Cologne, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, German Chronic Lymphocytic Leukemia Study Group, University of Cologne, Cologne, Germany

H

Hirushi Gunasekara

N

Neal Ramseier

1University of Illinois Chicago, Chemistry, Chicago, United States

I

Ira P. Maine

1Division of Hematology and Oncology, Department of Internal Medicine, University of Michigan, Ann Arbor, MI

A

Alejandro Zevallos-Morales

V

Vanessa Perez-Silos

A

Ashley Wolfe

1Division of Hematology and Oncology, Department of Internal Medicine, University of Michigan, Ann Arbor, MI

A

Alexandra C. Hristov

5Department of Pathology, University of Michigan, Ann Arbor, MI

N

Noah A. Brown

5Department of Pathology, University of Michigan, Ann Arbor, MI

K

Kedar Inamdar

3Henry Ford Hospital, Depart of Pathology, Detroit, United States

M

Maria Sverdlov

Y

Ying S. Hu

Department of Chemistry, University of Illinois Chicago, 845 W Taylor Street, Chicago, Illinois 60607, United States

C

Carlos Murga-Zamalloa

C

Chenguang Wang

R

Ryan A. Wilcox

23Division of Hematology/Oncology, University of Michigan Cancer Center, Ann Arbor, MI